A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

proportion of patients with the time from the date of first documented response until the date of documented progression or death in the absence of disease progression

proportion of patients with the time from randomization until the date of objective disease progression or death

the percentage of patients who have a best overall response of CR or PR or SD

the time from the date of randomization until death due to any cause

PROs will be assessed using the EORTC QLQ-C30,changes in score compared to baseline will be evaluated.

PROs will be assessed using the EORTC QLQ-LC13, changes in score compared to baseline will be evaluated.

To be assessed using the PRO CTCAE ,changes in symptoms compared to baseline will be evaluated.